Tokyo, Japan

Masashi Shimazaki


 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Masashi Shimazaki: Innovator in Pharmaceutical Development

Introduction

Masashi Shimazaki is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating lung cancer. With a total of 2 patents, his work is recognized for its potential impact on cancer treatment.

Latest Patents

One of Shimazaki's latest patents involves a quinazoline compound. This compound is designed to serve as an active ingredient in pharmaceutical compositions aimed at treating lung cancer. The research conducted by Shimazaki and his team revealed that this quinazoline compound exhibits excellent G12C mutation KRAS inhibitory activity. This discovery positions the compound as a promising therapeutic agent for lung cancer. The invention emphasizes the potential of the quinazoline compound and its salts in providing effective treatment options for patients.

Career Highlights

Masashi Shimazaki is currently associated with Astellas Pharma GmbH, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to advancing medical science and improving patient outcomes through innovative drug development.

Collaborations

Shimazaki collaborates with notable colleagues, including Kazuyuki Kuramoto and Michinori Akaiwa. Their combined expertise contributes to the success of their research and development efforts.

Conclusion

Masashi Shimazaki's contributions to pharmaceutical innovation, particularly in lung cancer treatment, highlight his role as a key inventor in the field. His work continues to inspire advancements in medical therapies that can significantly benefit patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…